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ORIGINAL ARTICLE
A sensitive and specific antigen detection assay for
Middle East respiratory syndrome coronavirus
Yixin Chen1,2, Kwok-Hung Chan3, Yahong Kang1,2, Honglin Chen3,4,5,6, Hayes KH Luk3, Rosana WS Poon3,
Jasper FW Chan3,4,5,6, Kwok-Yung Yuen3,4,5,6, Ningshao Xia1,2, Susanna KP Lau3,4,5,6 and Patrick CY Woo3,4,5,6
Since its emergence in 2012, more than 900 laboratory-confirmed cases of Middle East respiratory syndrome (MERS) have been
reportedwith a fatality rate ofmore than 30%.However, no antigen detection assay for commercial use is available for diagnosis. In this
study, the full-length nucleocapsid protein (NP) gene of MERS coronavirus (MERS-CoV) was cloned and expressed in Escherichia coli.
A MERS-CoV NP capture enzyme-linked immunosorbent assay (ELISA) using two MERS-CoV-NP-specific monoclonal antibodies
(MAbs) generated was developed. The ELISAwas evaluated using 129 nasopharyngeal aspirates (NPAs) positive for various respiratory
viruses and simulated positive NPAs by adding serial dilutions of MERS-CoV. Using a cutoff OD of 0.19, all 129 NPAs positive for
respiratory viruses showed very lowOD,with a specificity of 100%. For the two simulatedMERS-CoV-positiveNPAswith serial dilutions
of live MERS-CoV, all samples witho10 50% tissue culture infective dose (TCID50)/0.1 mL showed positive results. For the
10 additional NPAs with 20 and 200 TCID50/0.1 mL of live MERS-CoV added, all were positive. A highly sensitive and specific
MAbs-based antigen capture ELISA has been developed for MERS. This sensitive and specific antigen capture ELISA should be useful
for detection of MERS-CoV in human and dromedaries and in field studies.
Emerging Microbes and Infections (2015) 4, e26; doi:10.1038/emi.2015.26; published online 22 April 2015
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INTRODUCTION
Since its emergence in 2012,Middle East respiratory syndrome (MERS)
has affected more than 20 countries globally with a total of more than
900 laboratory-confirmed cases and a fatality rate of over 30%. Similar
to severe acute respiratory syndrome (SARS), MERS is also caused by a
coronavirus (CoV), named MERS-CoV;1–4 but unlike the SARS epi-
demic which has rapidly died off after the intermediate amplification
animal hosts were segregated from humans by closure of wild animal
markets in southern China, the MERS epidemic has persisted for more
than two years with no signs of abatement. The persistence of the
epidemic may be partly due to the difficulty to control the contact
between the people and dromedary camels, a major zoonotic source
of MERS-CoV.5–9 Since there is still no effective anti-viral agent for the
treatment of MERS-CoV infections, rapid and accurate laboratory dia-
gnosis is essential for commencement of infection control measures.
AlthoughMERS-CoV can be cultured and antibody detectionmeth-
ods are available, laboratory diagnosis of humanMERS-CoV infections
is mainly achieved by quantitative real-time RT-PCR, using the RNA-
dependent RNA polymerase, the region upstream to the envelope gene
or the nucleocapsid gene ofMERS-CoV as the target.10–13 However, the
cost of quantitative real-time RT-PCR is still high and such expertise
may not be available, particularly in the clinical microbiology labo-
ratories in the Middle East where most of the cases were identified.
Enzyme-linked immunosorbent assay (ELISA) for antigen detection
offers an inexpensive and user-friendly way for laboratory diagnosis
of respiratory viral infections, including SARS.14,15 As for MERS,
antigen detection ELISA will be useful not only for laboratory diagnosis
of patients with suspected MERS but also for field studies on drom-
edaries as well as other suspected animal reservoirs. So far, such an
antigen detection assay is not available for MERS-CoV. In this article,
we report the development and evaluation of a monoclonal antibody
(MAb)-based capture ELISA for MERS-CoV nucleocapsid protein
(NP) detection.
MATERIALS AND METHODS
Cloning and purification of (His)6-tagged recombinant NP (rNP)
of MERS-CoV
A clinical isolate ofMERS-CoVwas kindly provided byRAFouchier and
colleagues.2 All workwith infectiousMERS-CoVwas performed inside a
biosafety level-2 cabinetwith standardoperatingprocedures in approved
biosafety level-3 facilities.16–18 Viral culture and RNA extraction were
performed as we described previously.9,16 To produce a plasmid for
protein purification, primers (59-GAA TTC ATG GCA TCC CCT
GCT GCA CCT-39 and 59-GTC GAC ATC AGT GTT AAC ATC AAT
CAT-39) were used to amplify the gene encoding the NP of MERS-CoV
by RT-PCR. The sequence coding for amino acid residues 1–413 of the
NP was amplified and cloned into the EcoRI and SalI sites of expression
vector pET-28a(1) (Novagen, Merck Millipore, Billerica, MA, USA) in
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frame and upstream of the series of six histidine residues. The rNP
protein was expressed in Escherichia coli ER2566 cells (Invitrogen, Life
Technologies, Grand Island, NY, USA) and purified using Ni-NTA
affinity chromatograph column (Novagen, Merck Millipore, Billerica,
MA, USA) according to the manufacturer’s instructions.
Production of anti-MERS-CoV-rNP MAbs
Anti-MERS-CoV-rNP MAbs were produced using a protocol as
described previously.19 Briefly, six-week-old female BALB/cmice were
immunized with 100 mg purified MERS-CoV-rNP emulsified in an
equal volume of Freund’s complete adjuvant (Sigma-Aldrich, Saint
Louis, MO, USA) subcutaneously. Two booster immunizations using
the same antigen emulsified in incomplete Freund’s adjuvant were
carried out on days 14 and 28. Blood samples were obtained from
the tail veins of the immunized mice and tested for titers against
purified MERS-CoV-rNP by ELISA on MERS-CoV-rNP-coated
microplates. After the final booster dose, the spleens of the mice were
removed, and splenocytes were fused with the mouse myeloma cell
line Sp2/0-Ag-14. Culture supernatant from individual hybridoma
clones was then screened against purified MERS-CoV-rNP by
ELISA. After subcloning three times by limiting dilution, stable hybri-
doma cells were injected into the abdominal cavity of a mouse to
produce ascitic fluid. The MAbs were purified first by precipitating
with 50% ammonium sulfate, then with diethylaminoethyl column by
high performance liquid chromatography. The concentrations of
purified IgGwere determined by their absorbance atOD280. All animal
procedures were approved officially by the Xiamen University
Institutional Committee for the Use and Care of Laboratory Animal.
Western blot analysis
Western blot analysis was performed according to our published pro-
tocol.20 Briefly, 1.5 mg purified (His)6-tagged rNPs of MERS-CoV,
human CoV (HCoV) 229E and HCoV-OC43 respectively were sub-
jected to 12% SDS-PAGE and were transferred to 0.22 mm nitrocellu-
lose membranes (GE Healthcare, Little Chalfont, Buckinghamshire,
UK). The membranes were blocked with 5% skim milk in Tris-
buffered saline and then incubated with mouse anti-MERS-CoV-
rNP immune sera at 37 6C for 60 min. Antigen–antibody interaction
was detected with 1:4000 diluted horseradish peroxidase (HRP)-
conjugated goat anti-mouse IgG (Novex, Life Technologies, Grand
Island, NY, USA) and visualized by 3,39,5,59-tetramethylbenzidine
(TMB) liquid substrates system for membranes (Sigma Aldrich,
Saint Louis, MO, USA).
Capture ELISA for detection of MERS-CoV NP
The capture ELISA for MERS-CoV-NP detection was developed as
described previously with minor modifications.21 Microplates (Sigma
Aldrich, Saint Louis, MO, USA) were pre-coated with the first anti-
MERS-CoV-rNP MAb 1F6 and incubated at 37 6C overnight with a
blocking reagent (phosphate-buffered saline with 2% sucrose, 0.2%
casein-Na, and 2% gelatin). Inactivated MERS-CoV, HCoV-229E,
HCoV-OC43, two influenza virus A strains, one influenza virus B strain
and one respiratory syncytial virus (RSV) strain, and purified rNPs of
MERS-CoV,HCoV-229E, andHCoV-OC43were diluted in phosphate-
buffered saline with 2% skim milk. The inactivated viral lysates were
diluted to the same virus titer of 106 TCID50 and further serially diluted.
Specifically, 50 mL of viral lysis buffer was added to the coated well and a
50 mL of sample (fixed concentrations of purifiedNPor viral cell culture
lysates) was then added to the wells in duplicates. The plate was shaken
for 2 min and incubated at 37 6C for 30 min. After thewells werewashed
five times, 100 mL of the second anti-MERS-CoV-rNP MAb 7C4 con-
jugated with HRP was added and the plate was incubated at 37 6C for
30 min. After five washes, detection was carried out by adding of 100 mL
TMB per well with incubation for 10 min followed by the addition of
50 mL 0.2 M H2SO4. The OD 450/630 nm was measured with a micro-
plate reader. The cutoff valuewas set as 0.151mean value of 20 human
nasopharyngeal aspirates (NPAs) negative for influenza A, B, and C
viruses, adenovirus, RSV, parainfluenza viruses 1–4, human rhino-
viruses, human metapneumovirus, HCoV-HKU1, HCoV-OC43,
HCoV-229E, HCoV-NL63, and MERS-CoV.
Evaluation of MERS-CoV-NP capture ELISA
NPAs from129 patients with viral respiratory tract infections (influenza
A virus (n 5 10), influenza B virus (n 5 10), influenza C virus (n 5 2),
adenovirus (n 5 10), RSV (n 5 10), parainfluenza virus 1 (n 5 5),
parainfluenza virus 2 (n 5 2), parainfluenza virus 3 (n 5 10), parain-
fluenza virus 4 (n 5 10), human rhinoviruses (n 5 30), humanmetap-
neumovirus (n 5 10), HCoV-HKU1 (n 5 5), HCoV-OC43 (n 5 5),
HCoV-229E (n 5 5), and HCoV-NL63 (n 5 5)) and simulatedMERS-
CoV positive NPAs were used for the evaluation of the ELISA. NPAs
positive for influenza C virus, parainfluenza virus 4, human rhino-
viruses, human metapneumovirus, and HCoVs were determined by
RT-PCR and those for the other respiratory viruses were determined
by indirect immunofluorescence assay as described in our previous
publications.22–26 MERS-CoV culture and titration were performed
as we described previously.16 Simulated MERS-CoV positive NPAs
were prepared by adding serial dilutions (1–500 000 TCID50/0.1 mL)
of MERS-CoV to two different NPAs and 20 TCID50/0.1 mL and
200 TCID50/0.1 mL of MERS-CoV to 10 additional NPAs negative
for the above mentioned respiratory viruses. The ELISA was performed
as described above, using 50 mL of each NPA sample.
RESULTS
Production and characterization of MERS-CoV-rNP
The full-length NP gene of MERS-CoV was cloned and expressed in
E. coli strain ER2566 with a stretch of six histidine residues at both the
N and C termini. The MERS-CoV-rNP, with a molecular weight of
46 kDa, was purified by Ni-NTA affinity chromatography and was
used to immunize BALB/c mice. Western blot showed that mouse
anti-MERS-CoV-rNP immune sera had good reactivity with MERS-
CoV andMERS-CoV-rNP, indicating that the expressedMERS-CoV-
rNP has similar antigenicity to native NP ofMERS-CoV (Figure 1). As
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Figure 1 Western blot analysis of mouse anti-MERS-CoV-rNP immune sera.
Proteins loaded include: MERS-CoV-rNP, lysate of MERS-CoV (MERS-CoV),
lysate of influenza A virus strain CA/04 (Flu CA/04), molecular weight marker.
The arrows indicate the size of the MERS-CoV-rNP.
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a control, the mouse anti-MERS-CoV-rNP immune sera did not react
with influenza A virus strain CA/04 (Figure 1). The high ELISA titer
of mouse anti-MERS-CoV-rNP immune sera confirmed that the
MERS-CoV-rNP has good immunogenicity in BALB/c mice, indi-
cating that the MERS-CoV-rNP was useful for generation of anti-
MERS-CoV-rNP MAbs (Figure 2).
Generation and characterization of anti-MERS-CoV-rNP MAbs
A total of 24 MAbs were generated againstMERS-CoV-rNP by ELISA.
Twelve of them were confirmed to be MERS-CoV-rNP-specific MAbs
by ELISA using MERS-CoV-rNP as well as HCoV-229E-rNP and
HCoV-OC43-rNP (Figure 3). The cloning, expression, and purifica-
tion procedures for HCoV-229E-rNP and HCoV-OC43-rNP were the
same as described for those ofMERS-CoV-rNP (data not shown). The
other 12 MAbs showed different degrees of cross-reactivity among the
three rNP proteins, suggesting that the NPs of different CoVs might
have some common epitopes.
Development of capture ELISA for detection of MERS-CoV NP
To establish a capture ELISA for MERS-CoV NP detection, two anti-
MERS-CoV-rNP-specific MAbs (1F6 and 7C4) were selected. MAb
1F6 was coated onto the microplate and MAb 7C4 was conjugated
with HRP. This ELISA showed a high sensitivity, with detection limit
to MERS-CoV-rNP of less than 1 ng/mL; and a high specificity, with
no detection for the HCoV-OC43-rNP and HCoV-229E-rNP
(Figure 4A). The high sensitivity was further confirmed with a detec-
tion limit of 103 TCID50 of inactivated viral lysate of MERS-CoV
culture and the high specificity was further confirmed with no detec-
tion for inactivated viral lysates of two HCoVs (HCoV-OC43 and
HCoV-229E), two influenza A virus strains (CA/4/2009(H1N1) and
Brisbane/10/2007(H3N2)), one influenza B virus strain (Florida/04/
2006), and one RSV strain (Figure 4B).
Evaluation of MERS-CoV-NP capture ELISA
The mean value of 20 human NPAs negative for influenza A, B, and C
viruses, adenovirus, RSV, parainfluenza viruses 1–4, human rhino-
viruses, human metapneumovirus, HCoV-HKU1, HCoV-OC43,
HCoV-229E, HCoV-NL63, and MERS-CoV was 0.04. Using a cutoff
of 0.19 (0.15 1 0.04), all 129 NPAs positive for various viral respir-
atory tract infections were negative, with mean OD 6 SD of 0.067 6
0.022 (Figure 5). Therefore, the specificity of the capture ELISA for
NPA is 100%. For the two simulated MERS-CoV positive NPAs with
serial dilutions (1–500 000 TCID50/0.1 mL) of liveMERS-CoV added,
all samples with o10 TCID50/0.1 mL showed positive results
(Figure 5). As for the 10 additional NPAs with 20 TCID50/0.1 mL
and 200 TCID50/0.1 mL of liveMERS-CoV added, all showed positive
results (Figure 5).
DISCUSSION
We report the development of a MAbs-based antigen capture ELISA
for MERS-CoV-NP. Our previous experience on SARS-CoV has
shown that SARS-CoV-NP detection in SARS patients is highly feas-
ible using an antigen capture ELISA-based method.14,15 Since NP is
also an important, highly immunogenic and abundantly expressed
structural protein inMERS-CoV, its detection using similar principles
should also be feasible. The NP protein is amore preferable target than
the S protein because theNPprotein is present inmuch higher amount
than the S protein. In this study, using hyperimmune sera obtained
from mice immunized with three doses of MERS-CoV-rNP, we con-
firmed that MERS-CoV-NP is abundantly present in inactivated
MERS-CoV cell cultures (Figure 2). The antigen capture ELISA was
designed using two different MAbs (1F6 and 7C4) with high and
specific antibody titers against MERS-CoV-rNP (Figure 3). As half
of the 24 MAbs generated showed different degrees of cross-reactivity
against HCoV-229E and/or HCoV-OC43, suggesting the possibility of
common epitopes across the different CoVs, this MAbs-based ELISA
should be much more specific than a polyclonal antibodies-based
ELISA using hyperimmune sera generated from two different kinds
of animals immunized with MERS-CoV-rNP. In addition to the high
specificity, we also observed that MERS-CoV-rNP and MERS-CoV-
NP can be detected by the present assay with a protein and inactivated
viral concentrations of as low as 1 ng/mL and 103 TCID50/mL respect-
ively (Figure 4).
Evaluation of the diagnostic test using control and simulated clin-
ical specimens showed that the present ELISA is highly sensitive and
specific for MERS-CoV. Using more than 120 NPAs positive with
various respiratory viruses, we showed that the antigen capture
ELISA is highly specific. Most importantly, NPAs positive for the four
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Figure 3 Reactivity of anti-MERS-CoV-rNP MAbs in ELISA. The MERS-CoV-rNP
was coated at 100 ng/well. 1:5000 dilution of HRP-conjugated goat anti-mouse
antibody was used as the secondary antibody. Normal mouse sera were used as
negative control.
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Figure 2 The ELISA titer of mouse anti-MERS-CoV-rNP immune sera. The
MERS-CoV-rNP was coated at 100 ng/well. 1:5000 dilution of HRP conjugated
Goat anti-mouse antibody was used as second antibody. Normal mouse sera
were used as negative control.
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human CoVs all showed very low OD values by the present MERS-
CoV antigen detection assay, as the MERS-CoV-NP only shares
18.1%, 19.1%, 30.5%, and 30.5% amino acid identities with those of
HCoV-229E (alphaCoV), HCoV-NL63 (alphaCoV), HCoV-OC43
(betaCoV), and HCoV-HKU1 (betaCoV) respectively. As there have
been no importedMERS cases inHongKong so far andwe do not have
access to any MERS patient samples, we used simulated NPAs spiked
with live MERS-CoV for evaluation. Since the assay is able to detect
simulated NPA samples with viral load as low as 10 TCID50/0.1 mL of
live MERS-CoV, this diagnostic tool should be suitable for early dia-
gnosis of MERS, since the viral loads in NPAs of patients during acute
infection are usually around 106 copies/mL.27,28
The present MERS-CoV-NP capture ELISA is potentially useful for
detectingMERS-CoV in dromedary camel samples and screening other
animal specimens for MERS-CoV. Although the ancestral origin of
MERS-CoV is believed to be from bats,29–31 dromedaries are likely to
be the immediate animal reservoir for transmission of MERS-CoV to
human. High titers of antibodies to MERS-CoV have been detected in
more than 95% of adult dromedaries in the Middle East,5,9,32,33 and
MERS-CoV have also been found from the nasal samples of a small
proportion of dromedaries.8,34–36 As MERS-CoV was also detected in
the nasal samples in dromedaries with viral loads of around 104 to
106 copies/mL,37 the present ELISA should be readily useful for detect-
ing MERS-CoV in dromedaries. To prevent MERS infections as well as
in cases of MERS outbreaks, it may be necessary to screen and isolate
dromedaries that are actively shedding MERS-CoV. Since the present
ELISA captures MERS-CoV-NP antigen, it should be able to detect
MERS-CoV regardless of the source of the specimen, and should be
extremely useful for assessing viral shedding patterns in dromedaries as
well as searching for other animal sources of MERS-CoV.
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This antigen detection ELISA is suitable for clinical use and field
studies in the Middle East where most cases of MERS have occurred.
So far, most patients with MERS either resided in or had recent travel
histories to the Middle East. Therefore, a MERS diagnostic test
developed should be able to be used in clinical microbiology laborat-
ories in the Middle East. As for the animal reservoirs, the infected
dromedaries also live in the Middle East as well as North Africa.
Compared to quantitative real-time RT-PCR, the consumable cost of
the present antigen capture ELISA is lower. It also does not require
expertise onmolecular technology and the expensive set-up formolecu-
lar studies, which may not be present in most clinical microbiology
laboratories in the Middle East. For example, about 15 million people,
including more than two million pilgrims, visit Mecca in Saudi Arabia
every year. In particular, a high concentration of visitors is expected
during the Hajj period. A user-friendly laboratory test would be neces-
sary for handling such a large number of exposed people as well as
potential outbreaks because of mass gathering. Therefore, the present
ELISA is likely to be more suitable than quantitative real-time RT-PCR
for the use in laboratories in the Middle East and North Africa, where
resources and expertise could be limited. As for animals, this test would
be extremely useful for tracking the transmission patterns of MERS-
CoV among the dromedaries in the same farm as well as across different
countries. Further refinement of the test and the development of a rapid
antigen detection kit for on-the-spot diagnosis are warranted.
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